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Background: The rs2736100 single nucleotide polymorphism (SNP) is located in the
intron 2 of human telomerase reverse transcriptase (hTERT ) gene. Recent genome-wide
association studies (GWAS) have consistently supported the strong association between
this SNP and risk for multiple cancers. Given the important role of the hTERT gene and
this SNP in cancer biology, we hypothesize that rs2736100 may also confer susceptibility
to anti-cancer drug sensitivity. In this study we aim to investigate the correlation between
the rs2736100 genotype and the responsiveness to anti-cancer agents in the NCI-60
cancer cell panel.
Methods and Materials: The hTERT rs2736100 was genotyped in the NCI-60 cancer cell
lines. The relative telomere length (RTL) of each cell line was quantified using real-time
PCR. The genotype was then correlated with publically available drug sensitivity data
of two agents with telomerase-inhibition activity: Geldanamycin (HSP90 inhibitor) and
RHPS4/BRACO19 (G-quadruplex stabilizer) as well as additional 110 commonly used
agents with established mechanism of action. The association between rs2736100 and
mutation status of TP53 gene was also tested.
Results: The C allele of the SNP was significantly correlated with increased sensitivity
to RHPS4/BRACO19 with an additive effect (r = −0.35, p = 0.009) but not with
Geldanamycin. The same allele was also significantly associated with sensitivity to
antimitotic agents compared to other agents (p = 0.003). The highest correlation was
observed between the SNP and paclitaxel (r = −0.36, p = 0.005). The telomere length
was neither associated with rs2736100 nor with sensitivity to anti-cancer agents. The
C allele of rs2736100 was significantly associated with increased mutation rate in TP53
gene (p = 0.004).
Conclusion: Our data suggested that the cancer risk allele of hTERT rs2736100
polymorphism may also affect the cancer cell response to both TERT inhibitor and
anti-mitotic agents, which might be attributed to the elevated telomerase-independent
activity of hTERT, as well as the increased risk for TP53 gene mutagenesis
conferred by the polymorphism. Detailed mechanisms need to be further
investigated.
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INTRODUCTION
Telomerase is a ribonucleoprotein enzyme complex that main-
tains telomere ends by addition of telomeric repeats to the 3′
hydroxyl ends of DNA strands in the telomeric region (Artandi
and DePinho, 2010). Telomeres are essential for protecting chro-
mosomal ends from degradation and preventing inappropriate
fusion and rearrangements. Human telomerase is composed of
two important subunits: telomerase RNA (hTERC or hTR) which
serves as the template for telomere elongation and telomerase
reverse transcriptase (hTERT) which possesses the catalytic activ-
ity to synthesize DNA from the RNA template (Newbold, 2002;
Shay and Wright, 2005; Artandi and DePinho, 2010). Telomerase
activity has been observed in about 90% of human cancers
and is strongly associated with cellular immortalization, which
is thought to be a prerequisite for malignant transformation
(Newbold, 2002; Artandi and DePinho, 2010).
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Telomerase role in maintenance of telomeres is strongly asso-
ciated with cellular immortalization, and emerging evidence
reports that telomerase may have the capacity to directly regulate
cancer-promoting pathways through several mechanisms, includ-
ing telomere elongation-independent activity (Stewart et al.,
2002; Blasco and Hahn, 2003; Smith et al., 2003; Cong and Shay,
2008; Parkinson et al., 2008; Mukherjee et al., 2011). For this
reason, telomerase is considered an ideal target for anticancer
therapeutics and several strategies for telomerase inhibition are
in development and have entered clinical trials (Ruden and Puri,
2013). One approach involves directly inhibiting hTERT cat-
alytic activity using small molecule inhibitors, immunotherapy,
and gene therapy (Ruden and Puri, 2013). Several approaches
to targeting telomerase activity have been developed includ-
ing: G-quadruplex stabilizers, tankyrase inhibitors, and HSP90
inhibitors. A G-quadruplex is a higher order structure that pro-
tects telomeric 3′-overhangs from being accessed by telomerase.
G-quadruplex ligands inhibit telomerase activity by stabilizing
G-quadruplex and may also trigger telomere uncapping by caus-
ing dissociation of telomere-associated proteins. Tankyrase and
HSP90 inhibitors block telomerase activity by inhibiting binding
of telomerase-associated proteins, leading to telomere uncapping
and cell apoptosis (Ruden and Puri, 2013).
Given the important role of hTERT in cancer biology, many
researchers sought to investigate whether genetic variation at the
hTERT gene is associated with cancer development (Fujiwara
et al., 2000; Shete et al., 2009; Din et al., 2011; Hu et al., 2011;
Kinnersley et al., 2012; Mocellin et al., 2012; Zou et al., 2012).
The rs2736100 single nucleotide polymorphism (SNP) is one of
the most consistently identified variants of the hTERT gene asso-
ciated with cancer risk in multiple studies (Shete et al., 2009;
Hu et al., 2011; Kinnersley et al., 2012; Mocellin et al., 2012;
Zou et al., 2012). Thirty-two studies thus far have reported a
statistically significant association between C allele of rs2736100
and susceptibility to bladder, lung, pancreatic and CNS tumors,
but interestingly associated with a decreased risk for testicular
cancer (Mocellin et al., 2012). These studies strongly suggested
that TERT genetic variation confers risk to cancer pathogene-
sis. Whether this variation affects cellular response to anticancer
agents and subsequently leads to inter-individual variability in
clinical outcomes remains uninvestigated thus far. We hypoth-
esize in this study that rs2736100 may confer susceptibility to
the sensitivity to anticancer treatment especially agents with
telomerase inhibition activities. To corroborate this hypoth-
esis, we chose the NCI-60 cancer cell panel as an in vitro
model to evaluate the relationship between rs2736100 and 2
agents with telomerase inhibition activity and additional 110
commonly used anticancer agents with known mechanism of
action.
MATERIALS AND METHODS
DNA EXTRACTION AND GENOTYPING
DNA samples of the NCI-60 cell panel were provided by
the Pharmacogenetics of Anti-cancer Agents Research Group
(PAAR). DNA was isolated from NCI-60 cancer cells (n = 58) in
our previous studies (Liu et al., 2007, 2009). The rs2736100 SNP
was genotyped using TaqMan® SNP genotyping assays (Applied
Biosystems, Foster City, CA). Amplification for rs2736100 was
conducted on a BioRad CFX96 Real-Time PCR Detection System
(Bio-Rad, Hercules, CA) with the following program: 95◦C for
10min, followed by 40 cycles of 92◦C for 15 s and 60◦C for 1min.
Data were analyzed with BioRad CFX Manager software. A total
of 9 samples with an ambiguous genotyping call in the Taqman
assay were also PCR amplified and sequenced to confirm the
genotypes.
MEASUREMENT OF RELATIVE TELOMERE LENGTH (RTL)
The copy number of the telomere repeat (T) relative to the mean
copy number (S) of two single copy control genes 36B4 (encod-
ing acidic ribosomal phosphoprotein P0) and HBB (beta-globin)
were determined by real-time PCR. The result was expressed
as the T/S ratio. PCR primer sequences were according to the
previous report by Capezzone et al. (2008). All samples were
run in triplicates in a ViiA-7 Real-Time PCR system (Applied
Biosystems, CA, USA). In each run, a standard curve and a neg-
ative control were included. The final concentration of reagents
in the PCR were 1× SYBR Green Supermix, 300 nM Telomere
and 36B4 primers or 400 nM HBB primers and 2 ng DNA for
a final volume of 7.5 uL. Thermal cycling profile for the telom-
ere amplification was: 95◦C for 10min, followed by 40 cycles of
95◦C for 15 s and 54◦C for 1min. For 36B4 and HBB, ampli-
fication was 95◦C for 10min, followed by 40 cycles of 95◦C
for 15 s and 60◦C for 1min. To ensure the amplification speci-
ficity, a melting curve program was set as follows: 95◦C for
15 s, 60◦C for 1min, and 95◦C for 15 s, right after the PCR
cycles.
EXTRACTION OF CYTOTOXICITY DATA AND TP53 GENE MUTATION
DATA FROM THE NCI-60 DATABASE
Publically available GI50 (molar concentrations expressed as
log10[IC50]) data of two agents with telomerase inhibition
activity, a HSP90 inhibitor Geldanamycin (NSC330507) and G-
quadruplex stabilizer RHPS4/BRACO19 (NSC714187), as well
as 111 drugs with known mechanism of actions (Scherf et al.,
2000) were obtained from the NCI-60 database as described
in our previous study (Liu et al., 2009). The 111 drugs were
clustered into 6 main groups based on their cytotoxic activ-
ity: alkylating agents (n = 35), antimitotic agents (n = 16),
DNA antimetabolites (n = 15), RNA/DNA antimetabolites (n =
19), topoisomerase I inhibitors (n = 12) and topoisomerase II
inhibitors (n = 14). Due to the low variability in the GI50
data, an antimitotic drug NSC49842 was removed from the list.
Therefore, a total of 110 common drugs were included in the
analysis.
The method for drug sensitivity screening in the cancer cell
line panel was described in the NCI60 database (http://dtp.
nci.nih.gov/branches/btb/ivclsp.html). Note that the cytotoxic-
ity assays were not performed in our study. The protocol was
included in case one would follow to replicate the study. Briefly,
depending on the doubling time of each individual cell line
5000–40,000 cells/well were grown in 96-well microtiter plates
in 100µL at RPMI 1640 medium containing 5% fetal bovine
serum and 2mM L-glutamine. Cells were then incubated at
37◦C, 5% CO2, 95% air, and 100% relative humidity for 24 h
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prior to drug treatment. After incubation, two plates of each
cell line were fixed in situ with trichloroacetic acid (TCA). This
was used to be a measurement of the cell population for each
cell line at the time of drug addition (Tz). Each experimen-
tal drug was first solubilized in dimethyl sulfoxide (DMSO)
at the concentration that is 400-fold the desired final maxi-
mum test concentration. Solution was then aliquoted and stored
frozen until use. For each drug screening, one aliquot of frozen
concentrate was thawed and diluted to twice the desired final
maximum test concentration with complete medium containing
50µg/ml gentamicin. A total of five drug concentrations and con-
trol were made by 10-fold or ½ log serial dilutions. For each
concentration, 100µl of the drug dilution were aliquoted into
the appropriate microtiter wells that already contained 100µl of
medium, which resulted in the required final drug concentra-
tions. Medium in each plate was then mixed and incubated at
37◦C, 5% CO2, 95% air, and 100% relative humidity for 48 h.
For the detection of cytotoxicity, the assay was terminated by
the addition of cold TCA for adherent cells. Cells were then
fixed in situ by the gently adding 50µl of cold 50% (w/v)
TCA (final concentration, 10%) and incubated for 60min at
4◦C. After incubation, the supernatant was discarded, and the
plates were washed five times with tap water and air dried.
Cells were then stained by incubating in the plate for 10min
at room temperature by adding sulforhodamine B (SRB) solu-
tion (100µl) at 0.4% (w/v) in 1% acetic acid in each well.
After staining, unbound dye was discarded, followed by wash-
ing five times with 1% acetic acid and air dried. Bound stain
was subsequently solubilized by incubating with 10mM trizma
base, and the absorbance was read on an automated plate reader
at a wavelength of 515 nm. For suspension cells, the assay was
terminated by fixing settled cells at the bottom of the wells
by gently adding 50µl of 80% TCA (final concentration, 16%
TCA). The rest procedure was the same. The percentage growth
was calculated at each of the drug concentrations, by using
the seven absorbance measurements [time zero (Tz), control
growth (C), and test growth in the presence of drug at the
five concentration levels (Ti)], Percentage growth inhibition was
calculated as:
“[(Ti−Tz)/(C−Tz)]× 100 for concentrations forwhich Ti≥Tz
[(Ti − Tz) /Tz] × 100 for concentrations for which Ti < Tz.
Three dose response parameters (GI50, TGI, and LC50) were
calculated for each experimental agent. Growth inhibition of
50% (GI50) was calculated from [(Ti − Tz)/(C − Tz)] ×
100 = 50, which was the drug concentration resulting in a
50% reduction in the net protein increase (as measured by
SRB staining) following treatment as compared to the control
cells. The drug concentration resulting in total growth inhibi-
tion (TGI) was calculated from Ti = Tz. The LC50 (concen-
tration of drug resulting in a 50% reduction in the measured
protein at the end of the drug treatment as compared to
that at the beginning) indicating a net loss of cells follow-
ing treatment was calculated from [(Ti − Tz)/Tz] × 100 =
−50. Values were calculated for each of these three parame-
ters if the level of activity was reached; however, if the effect
was not reached or was exceeded, the value for that parameter
was expressed as greater or less than the maximum or min-
imum concentration tested.” (http://dtp.nci.nih.gov/branches/
btb/ivclsp.html).
Mutation status of TP53 gene was downloaded from the NCI-
60 database using the accession ID MT2924. The TP53 mutations
were identified using PCR-sequencing in previous study (Ikediobi
et al., 2006).
STATISTICS
Comparison of the genotype frequency between our data and
the Hapmap data as well as the test for Hardy–Weinberg
Equilibrium (HWE) were conducted using Chi-square test.
Associations between SNP genotype and cytotoxicity data as
well as relative telomere length (RTL) were first screened
using One-Way ANOVA with a statistical significance set
to p = 0.05. A post-hoc linear regression was performed to
identify the best genetic model. In doing so, SNP geno-
type was correlated with RTL or drug cytotoxicity data by
assigning each genotype to 0, 1, and 2 (additive model),
0, 0, and 1 (receive model) or 0, 1, and 1 (dominant
model) according to the number of C allele (Codd et al.,
2013). Association between SNP genotype and the cytotox-
icity data of a specific group of drugs was tested using
Fisher’s exact test based on a 2 × 2 contingency table, by
comparing the number of positive correlation (p < 0.05) in
a given group compared with that of the remaining drugs.
Correlation between RTL cytotoxicity data was performed using
linear regression. RTL data were log transformed (+log10)
prior to analyses. Association between rs2736100 and TP53
gene mutation status was performed using Chi-squared test
or Fisher’s exact test, with a statistical significance level
of p = 0.05.
RESULTS
GENOTYPING OF rs2736100
All 58 cell lines were successfully genotyped for rs2736100 poly-
morphism (Table S1). For the samples (n = 9) shown as out-
liers in the Taqman assay, PCR-sequencing was performed to
confirm the genotypes. Genotypes of all 9 samples were con-
cordant with the Taqman assay (data not shown). The fre-
quency of the AA, AC, and CC genotypes were 0.22, 0.48,
and 0.29, respectively. This result was very comparable to the
Hapmap data which is 0.22, 0.52, and 0.27 (Chi-square test,
df = 2, p = 0.88). No significant deviation from the Hardy–
Weinberg Equilibrium was observed (Chi-square test, df = 2,
p = 0.79).
QUANTIFICATION OF RELATIVE TELOMERE LENGTH (RTL)
The RTL was successfully quantified in 50 out 58 cell
lines. Measurement in eight cell lines was failed due to
the low DNA quality, thus removed from the final analy-
sis. Among the 50 cell lines, the median and min-max RTL
is 0.79, 0.12–23.66. Two melanoma cell lines LOX IMVI
and SK-MEL-28 were demonstrated to possess extremely long
RTL (23.66 and 6.65, respectively) compared to other cells
(Table S1).
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ASSOCIATION BETWEEN rs2736100 AND RESPONSE TO
TELOMERASE INHIBITORS
Rs2736100 was significantly associated with sensitivity to
RHPS4/BRACO19 (NSC714178) (ANOVA p = 0.027) with an
additive effect of the C allele (r = −0.35, p = 0.009) (Figure 1A)
but not with Geldanamycin (NSC330507) (ANOVA p = 0.69)
(data not shown).
ASSOCIATION BETWEEN rs2736100 AND OTHER
ANTI-CANCER AGENTS
Significant associations between rs2736100 and sensitivity to 4
out of 15 antimitotic agents were observed (ANOVA, NSC83265
p = 0.032; NSC125973 p = 0.017; NSC671867 p = 0.026; and
NSC673188, p = 0.039). This was in contrast to only 2 signif-
icant associations among the remaining 95 drugs (NSC79037
p = 0.014 and NSC755 p = 0.026), suggesting an overall asso-
ciation between the polymorphism and anti-mitotic agents
(Fisher’s exact test, p = 0.003). Consistently, there were also
marginal associations between the SNP and 3 additional anti-
mitotic agents (NSC153858 p = 0.058; NSC656178 p = 0.074;
and NSC666608 p = 0.069). Post-hoc linear regression analy-
sis demonstrated a significant dominant effect of the C allele
FIGURE 1 | Correlations between rs2736100 and cytotoxicity of
RHPS4/BRACO19 (A) and paclitaxel (B). SNP genotype was correlated
with drug cytotoxicity data by assigning each genotype (AA, AC, and CC) to
0, 1, and 2 (additive model), 0, 0, and 1 (receive model) or 0, 1, and 1
(dominant model) according to the number of C allele. The horizontal bars
indicate the mean value of each group. Linear correlation coefficient (r) and
p-value are indicated as well.
on the response to the aforementioned 7 antimitotic drugs,
again contrasting to only 3 significant/marginal associations
among the remaining 95 drugs (Fisher’s exact test, p <
0.0001). The linear correlation coefficient values were plotted
in Figure 2, where a consistent negative correlation between C
allele and sensitivity to all anti-mitotic drugs compared to other
groups of agents were demonstrated. Among all anti-mitotic
drugs, the most significant association was observed between
rs2736100 and paclitaxel (NSC125973, r = −0.36, p = 0.005)
(Figure 1B).
CORRELATIONBETWEEN RTL AND rs2736100 AND CYTOTOXICITY DATA
No significant association between rs2736100 andRTLwas found.
There was also no significant correlation between RTL and cyto-
toxicity data for any group of anti-cancer agents (p > 0.05, data
not shown).
ASSOCIATION BETWEEN rs2736100 AND TP53 MUTATIONS
According to the previous study (Ikediobi et al., 2006), TP53
mutations were found in 42 cell lines, including 12 heterozy-
gous and 30 homozygous mutations. There was a significant
association between rs2736100 and the TP53 mutation status
in the NCI-60 panel (overall Chi-squared test in the 3 × 3
table p = 0.03), with 82% (37 out of 45) of C-allele carriers
(AC + CC) harboring mutations (heterozygous + homozygous)
as compared to only 38% (5 out of 13) of the AA genotype
(Fisher’s exact test, OR = 7.4, 95% CI = 1.9–28.7, p = 0.004)
(Table 1).
DISCUSSION
The genetic basis underlying susceptibility to sensitivity
and resistance to anti-cancer treatment remains largely
unknown. Identifying genetic factors conferring this
susceptibility may lead to personalized treatment for can-
cers. Our results suggested that a common risk allele
increasing susceptibility to various cancers might also
FIGURE 2 | Linear correlation coefficient (r) between rs2736100 and
cytotoxicity of 110 anti-cancer drugs grouped in 6 mechanisms of
action. The figure showed here that compared to other groups of drugs,
the GI50s of anti-mitotics were consistently and negatively correlated with
rs2736100 genotype in an additive model (0, 1, and 2 corresponding to AA,
AC, and CC), suggesting an association between the C allele and increased
sensitivity to anti-mitotics.
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Table 1 | Association between rs2736100 and TP53 mutations.
TP53 mut rs2736100 genotypes
AA AC CC
wt 8 (62%) 4 (14%) 4 (24%)
het 2 (15%) 7 (25%) 3 (18%)
hom 3 (23%) 17 (61%) 10 (59%)
Showing here are the number and percentage of samples with different muta-
tion status among each of the three genotypes. Mut, mutation; wt, wildtype;
het, heterozygous; hom, homozygous.
influence the efficacy of anti-telomerase and anti-mitotic
agents.
The C allele of rs2736100 has been associated with increased
risk for multiple cancers, including lung, bladder, pancreatic can-
cer and glioma (Shete et al., 2009; Hu et al., 2011; Kinnersley
et al., 2012; Mocellin et al., 2012; Zou et al., 2012). How this
allele functions and increases cancer risk remains incompletely
understood. Although it is possible that other SNPs in linkage
disequilibrium (LD) with this SNP may be more causal to the
overall effect, a bioinformatics study suggested that rs2736100
may be located in a regulatory region of the hTERT gene (Zou
et al., 2012). Most significantly, the C allele was highly associated
with longer telomere length of germ-cells in a few recent stud-
ies including a genome-wide association study (Melin et al., 2012;
Codd et al., 2013). Since the hTERT gene is widely activated in
most cancers compared to normal cells, it is highly likely that dur-
ing carcinogenesis the C allele, and/or its LD proxies, increases
the hTERT expression and subsequently confer a higher telom-
erase activity. Our results demonstrated that the C allele increases
the risk for the development of p53 mutations in cancer cells, sug-
gesting that this allele and the associated increased hTERT activity
may be beneficial to mutagenesis, thus potentially explaining the
association between this allele and the susceptibility to multiple
cancers. Further investigation will require a detailed identifica-
tion of all polymorphisms around the rs2736100 region followed
by a mechanistic evaluation of functional pathways that these
polymorphisms may alter. However, no significant association
between rs2736100 and RTL was found in our dataset. While this
might be due to the limited power attributed to the small sample
size (n = 50), it is also possible that the telomere length of trans-
formed cells might be significantly different from the original
germ-cell.
Our study observed a significant correlation between the
rs2736100 C allele and sensitivity to a G-quadruplex stabilizer
RHPS4/BRACO19, but not Geldanamycin, a HSP90 inhibitor.
This discrepancy may reflect the difference in the mechanism of
action of the two drugs. While G-quadruplex stabilizers block
access of telomerase to telomeres, HSP90 inhibitors prevent the
assembly of telomerase-associated proteins required for hTERT
promoter activity (Ruden and Puri, 2013). However, HSP90 is
implicated in many other processes that contribute to carcino-
genesis.
Our results also demonstrated that the rs2736100 C allele may
specifically influence the cellular response to anti-mitotic agents
compared to other commonly used drugs. Anti-mitotics are drugs
that disrupt mitotic progression, and have been used extensively
for the treatment of cancer (Gascoigne and Taylor, 2009). Anti-
mitotics inhibit the function of microtubules by either binding to
their subunits or by preventing their growth (Lee et al., 2004). In
both cases normal mitotic spindle formation is disrupted, caus-
ing cell cycle arrest and eventually apoptosis (Blagosklonny and
Fojo, 1999; Park et al., 2011). Previous studies have indicated
that the hTERT gene might be involved in the spindle assembly
checkpoint. This effect may or may not necessarily be confined
to hTERT’s function in maintaining telomere length (Belivaeu
et al., 2007). This is consistent with our observation that there
was no significant correlation between RTL of these cells and their
response to anti-cancer agents. The telomere length-independent
activity of hTERT has been widely observed in cancer cells, e.g.,
immunofluroescent staining for hTERT in human breast can-
cer cells has showed that hTERT might be potentially involved
in the G2/M mitotic spindle function and checkpoint in mitosis
(Belivaeu et al., 2007), whereas activation of a functional spindle
assembly checkpoint is required for paclitaxel-induced cell death
(Sudo et al., 2004; Yamada and Gorbsky, 2006). Furthermore,
as the most commonly mutated gene in various human cancers,
TP53 plays critical roles in mitosis by acting as the cell cycle G1
phase checkpoint and by regulating the spindle checkpoint (Fang
and Zhang, 2011). The strong association between rs2736100 and
TP53 mutations in our study suggests that rs2736100 may be
prone to retain TP53 mutagenesis during cancer development,
while mutated p53 might mediate at least in part the associa-
tion between rs2736100 and increased sensitivity to anti-mitotics.
Our finding is consistent with previous observations, e.g., ectopic
expression of hTERT in HMECs resulted in reduced basal level
of active p53 (Belivaeu et al., 2007), while p53 deficient RKO
colorectal cancer cells were four times more sensitive to pacli-
taxel compared to wild type RKO cells (Rakovitch et al., 1999).
Nevertheless, as thus far the hTERT function in carcinogenesis,
its interaction with other molecules as well as its activity inde-
pendent of the telomere maintenance are still poorly understood,
further investigation will be necessary to completely elucidate the
mechanism underlying the observations in our study.
In conclusion, our study suggests that inherently increased
hTERT function may play an important role in cancer devel-
opment and may also affect efficacy of anti-cancer agents.
Continued studies in both the in vitro and in vivo settings are
warranted.
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